- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02067130
Utility of Fibroscan in Estimating Hepatic Iron Concentration
Utility of Transient Elastography (Fibroscan) in Estimating Hepatic Iron Concentration in Comparison to MRI in Patients With Transfusion Dependent Hemoglobinopathies
In patients with hereditary anemias (e.g. thalassemias), defective red blood cells are produced due to an error in the genes, or DNA, that provide the instructions for their synthesis. As a result, hereditary anemias are characterized by chronically low hemoglobin, which is contained inside red blood cells and carries oxygen throughout the body. In more severe cases, patients are dependent on frequent blood transfusions to replenish the hemoglobin.
The body has limited ability to get rid of excess iron. However, with repeated blood transfusions, the iron level in the body builds up because the red blood cells contain iron as heme. Over time, the high level of iron accumulates in organs such as the heart, liver, and pancreas causing heart problems, liver failure, and diabetes. As a result, patients who receive multiple blood transfusions need to be monitored for iron overload, and be started on medical therapy in a timely fashion to prevent organ damage.
Liver is usually the first and the most affected organ by iron accumulation, so knowledge of its iron concentration provides estimate of total body iron load. Liver biopsy is the gold standard in measuring the iron concentration in the liver, but it is invasive and cannot be performed on routine basis. MRI is another option that can assess liver iron concentration non-invasively, and is currently recommended for monitoring iron load on a yearly basis. However, MRI has a high cost and is not easily accessible in Canada. The investigators aim to determine if transient elastography (Fibroscan), which is a form of ultrasound that measures liver stiffness, can accurately assess liver iron concentration.
Hypothesis:
Fibroscan reading correlates with MRI and serum ferritin in estimating hepatic iron concentration.
Study Overview
Detailed Description
Inclusion criteria: All adult patients (age 19 or greater) with hereditary anemias requiring chronic blood transfusion at St. Paul's Hospital will be invited to participate in this study. The majority of patients will be β-Thalassemia Major. They will be given a pamphlet containing the details of the study and can contact the research assistant or clinic nurse for more information should they be interested.
Exclusion criteria: Patients with known Hepatitis B positive, known Hepatitis C positive, known HIV positive, known liver cirrhosis, known primary liver disease such as Wilson's disease and hereditary hemochromatosis are excluded from the study.
Written consent will be obtained from all participants by the clinic nurse/research assistant prior to enrollment.
Study procedures:
Data to be collected retrospectively from patient charts (St. Paul's Hospital's EMR/Sunrise Clinical Manager and paper chart) include: baseline demographic data (age, gender, hematological condition), medical comorbidities and complications related to iron overload (Diabetes, hypothyroidism, cardiomyopathy/arrhythmia and congestive heart failure, hypogonadotropic hypogonadism, osteopenia and osteoporosis syndrome..etc), current medications including use of iron chelators such as desferrioxamine, deferasirox, deferiprone or combination therapy, viral hepatitis status (B and C) and date of test, liver cirrhosis status (stage), liver biopsy result (iron concentration) and date of procedure. Patients with chronic transfusion requirement usually undergo annual MRI at the beginning of the year to estimate hepatic iron concentration as per standard practice. This year (2013), R2 MRI (FerriScan) will also be available for the first time to all patients in BC as part of routine monitoring for iron overload. Details/results from both techniques (i.e. same images collected in one scan, but analyzed differently using R2 and T2* algorithms) will be collected.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 1Y6
- St. Paul's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All adult patients (age 19 or greater) with hereditary anemias requiring chronic blood transfusion at St. Paul's Hospital will be invited to participate in this study. The majority of patients will be β-Thalassemia Major.
Exclusion Criteria:
- Known Hepatitis B positive
- Known Hepatitis C positive
- Known HIV positive
- Known liver cirrhosis
- Known primary liver disease such as Wilson's disease and hereditary hemochromatosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Fibroscan
Subjects enrolled will undergo Fibroscan.
It is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis.
Fibroscan reading will be collected at the Gastroenterologist's (Dr.
Ko) outpatient clinic (Pacific Gastroenterology Associates) where a qualified research nurse/assistant will perform the scan under supervision of the physician.
Anticipated timing of this procedure will be October to December 2013
|
Transient elastography (Fibroscan®) is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis.
Since Fibroscan® measures liver's stiffness, its utility is not limited to fibrosis, and has been extended to other conditions that would increase the liver's stiffness, such as amyloidosis (Loustaud-Ratti et al.
Amyloid 2011) and perhaps iron overload.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fibroscan reading collected at the Gastroenterologist's outpatient clinic
Time Frame: 1 year
|
Fibroscan results will be compared to that of T2* MRI, R2 MRI (FerriScan) and serum ferritin using linear regression models to determine if there is any correlation between FibroScan® results and liver iron concentration, which is indirectly measured with MRI and serum ferritin.
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hatoon Ezzat, MD, Department of Medicine, Division of Hematology St. Paul's Hospital, University of British Columbia
- Principal Investigator: Hinhin Ko, MD, Department of Medicine, Division of Gastroenterology, St. Paul's Hospital, University of British Columbia
Publications and helpful links
General Publications
- Shander A, Sazama K. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy. Transfusion. 2010 May;50(5):1144-55. doi: 10.1111/j.1537-2995.2009.02551.x. Epub 2010 Jan 15.
- Jung KS, Kim SU. Clinical applications of transient elastography. Clin Mol Hepatol. 2012 Jun;18(2):163-73. doi: 10.3350/cmh.2012.18.2.163. Epub 2012 Jun 26.
- Loustaud-Ratti VR, Cypierre A, Rousseau A, Yagoubi F, Abraham J, Fauchais AL, Carrier P, Lefebvre A, Bordessoule D, Vidal E, Sautereau D, Jaccard A. Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool. Amyloid. 2011 Mar;18(1):19-24. doi: 10.3109/13506129.2010.543443. Epub 2011 Jan 10.
- Remacha A, Sanz C, Contreras E, De Heredia CD, Grifols JR, Lozano M, Nunez GM, Salinas R, Corral M, Villegas A; Spanish Society of Blood Transfusion; Spanish Society of Haematology and Haemotherapy. Guidelines on haemovigilance of post-transfusional iron overload. Blood Transfus. 2013 Jan;11(1):128-39. doi: 10.2450/2012.0114-11. Epub 2012 Jul 4. No abstract available.
- Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V, Deugnier Y. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004 Jan 31;363(9406):357-62. doi: 10.1016/S0140-6736(04)15436-6.
- Hou P, Popat UR, Lindsay RJ, Jackson EF, Choi H. A practical approach for a wide range of liver iron quantitation using a magnetic resonance imaging technique. Radiol Res Pract. 2012;2012:207391. doi: 10.1155/2012/207391. Epub 2012 Dec 11.
- Argyropoulou MI, Astrakas L. MRI evaluation of tissue iron burden in patients with beta-thalassaemia major. Pediatr Radiol. 2007 Dec;37(12):1191-200; quiz 1308-9. doi: 10.1007/s00247-007-0567-1. Epub 2007 Aug 21.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- H13-02149
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hereditary Anemias
-
Aristotle University Of ThessalonikiNational and Kapodistrian University of Athens; European University CyprusCompletedGlutathione Metabolism AnemiasCyprus, Greece
-
HaEmek Medical Center, IsraelCompleted
-
Sohag UniversityAssiut UniversityActive, not recruiting
-
National Institute of Diabetes and Digestive and...TerminatedHemoglobinopathies | Hemolysis | Iron Deficiency and Overload | AnemiasUnited States
-
Novartis PharmaceuticalsCompletedChronic Iron Overload Due to Transfusion-dependant AnemiasItaly, Austria, Thailand, Spain, Germany, Mexico, Malaysia, Greece, United Kingdom, France, Saudi Arabia, United Arab Emirates, Lebanon, Russian Federation, United States, Argentina
-
Memorial Sloan Kettering Cancer CenterCompletedBeta Thalassemia Major | Congenital AnemiasUnited States
-
Pharvaris Netherlands B.V.CompletedHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditionsBulgaria, United States, Spain, Israel, Germany, Canada, Czechia, France, Hungary, Italy, Netherlands, Poland, United Kingdom
-
Pharvaris Netherlands B.V.Active, not recruitingHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditionsUnited States, Poland, Germany, Austria, Bulgaria, Canada, Ireland, Italy, United Kingdom
-
University of UtahUniversity of Witwatersrand, South AfricaCompletedHereditary Elliptocytosis (HE) | Hereditary Pyropoikilocytosis (HPP)United States
-
University of Texas Southwestern Medical CenterRecruiting
Clinical Trials on Fibroscan
-
EchosensRecruitingSpleen; FibrosisSpain, Netherlands, Romania
-
Assiut UniversityNot yet recruiting
-
Helen Kovari-KramerSwiss HIV Cohort StudyUnknownHIV Infection and Chronic Alanine Aminotransferase ElevationSwitzerland
-
Centre Hospitalier Universitaire DijonCompletedHepatic Steatosis | Pituitary Gland FailureFrance
-
HaEmek Medical Center, IsraelTerminatedPatients With Fatty Liver DiseaseIsrael
-
Icahn School of Medicine at Mount SinaiNational Institutes of Health (NIH)CompletedNASH - Nonalcoholic Steatohepatitis | Steatosis of LiverUnited States
-
Assistance Publique - Hôpitaux de ParisTerminatedHepatitis, Viral, HumanFrance
-
University of AarhusActive, not recruitingLiver Inflammation | Primary Biliary CirrhosisDenmark
-
Nantes University HospitalRecruiting
-
Assiut UniversityUnknownStudy of the NAFLD in CKD Patients Using Fibroscan Study